FI972584A0 - Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi - Google Patents

Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi

Info

Publication number
FI972584A0
FI972584A0 FI972584A FI972584A FI972584A0 FI 972584 A0 FI972584 A0 FI 972584A0 FI 972584 A FI972584 A FI 972584A FI 972584 A FI972584 A FI 972584A FI 972584 A0 FI972584 A0 FI 972584A0
Authority
FI
Finland
Prior art keywords
atherosclerosis
ones
treatment
substituted azetidin
azetidin
Prior art date
Application number
FI972584A
Other languages
English (en)
Swedish (sv)
Other versions
FI972584A (fi
Inventor
Deirdre Mary Bernadette Hickey
Colin Andrew Leach
Robert John Ife
David Graham Tew
Dashyant Dhanak
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426020.5A external-priority patent/GB9426020D0/en
Priority claimed from GBGB9426030.4A external-priority patent/GB9426030D0/en
Priority claimed from GBGB9511599.4A external-priority patent/GB9511599D0/en
Priority claimed from GBGB9511600.0A external-priority patent/GB9511600D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of FI972584A0 publication Critical patent/FI972584A0/fi
Publication of FI972584A publication Critical patent/FI972584A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
FI972584A 1994-12-22 1997-06-17 Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi FI972584A (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9426020.5A GB9426020D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9426030.4A GB9426030D0 (en) 1994-12-23 1994-12-23 Novel compounds
GBGB9511599.4A GB9511599D0 (en) 1995-06-08 1995-06-08 Novel compounds
GBGB9511600.0A GB9511600D0 (en) 1995-06-08 1995-06-08 Novel compounds
PCT/EP1995/005130 WO1996019451A1 (en) 1994-12-22 1995-12-20 Substituted azetidin-2-ones for treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
FI972584A0 true FI972584A0 (fi) 1997-06-17
FI972584A FI972584A (fi) 1997-08-19

Family

ID=27451242

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972584A FI972584A (fi) 1994-12-22 1997-06-17 Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi

Country Status (24)

Country Link
US (1) US5990102A (fi)
EP (1) EP0799200A1 (fi)
JP (1) JPH11500415A (fi)
CN (1) CN1175246A (fi)
AP (1) AP9701007A0 (fi)
AR (1) AR002012A1 (fi)
AU (1) AU704407B2 (fi)
BG (1) BG101687A (fi)
BR (1) BR9510420A (fi)
CA (1) CA2208530A1 (fi)
CZ (1) CZ192297A3 (fi)
DZ (1) DZ1958A1 (fi)
FI (1) FI972584A (fi)
HU (1) HUT77089A (fi)
IL (1) IL116485A0 (fi)
MA (1) MA23834A1 (fi)
MX (1) MX9704736A (fi)
NO (1) NO972909L (fi)
NZ (1) NZ298416A (fi)
OA (1) OA10737A (fi)
PL (1) PL320937A1 (fi)
SK (1) SK80397A3 (fi)
TR (1) TR199501655A2 (fi)
WO (1) WO1996019451A1 (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK178497A3 (en) * 1995-07-01 1998-07-08 Smithkline Beecham Plc Azetidinone derivatives, method for producing the same, pharmaceutical composition containing same and their use
WO1997021676A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
EP0869943A1 (en) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
EP0915843A1 (en) * 1996-04-26 1999-05-19 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atheroscleroses
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
AU4654199A (en) * 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
CZ304450B6 (cs) 2000-02-16 2014-05-14 Smithkline Beecham P. L. C. Pyrimidinový derivát
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1747014A4 (en) * 2004-05-03 2007-09-12 Ilypsa Inc MODULATION OF LYSOPHOSPHATIDYLCHOLINE AND TREATMENT OF CONDITIONS INDUCED BY A DIET
EP2152865B1 (en) 2007-05-11 2015-04-15 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
EA018101B1 (ru) 2007-05-11 2013-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения кожных язв
CA2820408C (en) 2010-12-06 2018-03-06 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US20140171431A1 (en) 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
CA2843102A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Bicyclic pyrimidone compounds
KR20140059203A (ko) 2011-07-27 2014-05-15 글락소 그룹 리미티드 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
CN105008368B (zh) 2013-01-25 2017-02-01 葛兰素史密斯克莱知识产权发展有限公司 基于2,3‑二氢咪唑并[1,2‑c]嘧啶‑5(1H)‑酮的脂蛋白相关磷脂酶A2(Lp‑PLA2)抑制剂
BR112015017397A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos pirimidona bicíclica como inibidores de lp-pla2
WO2015179293A1 (en) * 2014-05-18 2015-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule activators and inhibitors of lecithin: cholesterol acyltransferase
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CA3156783A1 (en) 2019-11-09 2021-05-14 Yun Jin Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010358A1 (en) * 1978-09-20 1980-04-30 Glaxo Group Limited Beta-lactam compounds, processes for their preparation, compositions containing them, intermediates of use in their preparation and methods for the production thereof
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPH11500415A (ja) 1999-01-12
AU704407B2 (en) 1999-04-22
TR199501655A2 (tr) 1996-07-21
MX9704736A (es) 1997-10-31
CA2208530A1 (en) 1996-06-27
EP0799200A1 (en) 1997-10-08
SK80397A3 (en) 1998-01-14
MA23834A1 (fr) 1996-10-01
OA10737A (en) 2002-12-10
IL116485A0 (en) 1996-08-04
WO1996019451A1 (en) 1996-06-27
AR002012A1 (es) 1998-01-07
AP9701007A0 (en) 1997-07-31
CZ192297A3 (en) 1997-11-12
NO972909L (no) 1997-08-20
US5990102A (en) 1999-11-23
PL320937A1 (en) 1997-11-10
AU4389896A (en) 1996-07-10
BG101687A (en) 1998-02-27
FI972584A (fi) 1997-08-19
NZ298416A (en) 1999-03-29
BR9510420A (pt) 2004-04-20
HUT77089A (hu) 1998-03-02
DZ1958A1 (fr) 2002-02-17
CN1175246A (zh) 1998-03-04
NO972909D0 (no) 1997-06-20

Similar Documents

Publication Publication Date Title
FI972584A0 (fi) Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi
FI954880A (fi) Käsiteltyjä epäorgaanisia kiintoaineita
DK0777671T3 (da) Spiro-azabicykliske forbindelser
ZA959100B (en) Azetidinone derivatives for the treatment of atherosclerosis
DE69520558T2 (de) Halogenierungsverfahren
NO976158D0 (no) Azetidinon-derivater for behandling av atherosklerose
BR9709196A (pt) Derivados de azetidinona para o tratamento de aterosclerose
ID17723A (id) Senyawa untuk pengobatan
DE69520998D1 (de) Faserbehandlungszusammensetzungen
IS4789A (is) Meðferðarefnasambönd
FI970151A (fi) Viruksenvastaisesti vaikuttavia difluoristatoniyhdisteitä
DE69507032D1 (de) Chlorhydrin-verfahren
BR9509740A (pt) Compostos 18-nor-vitamina d
DE9400356U1 (de) Gehwagen
DE69417067D1 (de) Verbundstoffe
NO962812D0 (no) Fremgangsmåte for behandling av nervebetennelse
KR960022630U (ko) 용광로의 풍구
FI973780A0 (fi) Arrangemang foer bestaemning av laekemedelsdosering
UA25833C2 (uk) Засіб для лікуваhhя мелаhомобластом
FI943432A0 (fi) Tillverkning av plastroerelement foersett med loesmuffoerbandsmedel
FI943862A0 (fi) Foerfarande foer framstaellning av en kretsmoensterfolie
FI943255A0 (fi) I en mapp faestbar perforeringsapparat foer papper
FI1363U1 (fi) Anlaeggning i pappersmaskin i samband med kantsprutroeren
FI1727U1 (fi) Ansiktsskydd i samband med haortvaettning
SE9404416D0 (sv) Novel compounds